# Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation

> **NCT02172508** · PHASE4 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 15 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium Inhalation Capsule
- **DRUG:** Placebo Lactose Capsule

## Key facts

- **NCT ID:** NCT02172508
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2004-03
- **Final completion:** —
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02172508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02172508, "Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02172508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*